SCHEMBL6286338

SCHEMBL6286338

Cc1cc(=O)c2c(=O)n(CCCCC(C)O)c(=O)n(C)c2n1Cc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.39
NOTUM Q6P988 1/20 0.39
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALOX15 P16050 1/20 0.37
HTT P42858 1/20 0.37
LGMN Q99538 1/20 0.36
MEN1 O00255 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286332 1.00 SMN1; SMN2 (0.40) SMN1; SMN2MAPK1RAB9AKMT2ANOTUM
SCHEMBL6289981 1.00 SMN1; SMN2 (0.40) SMN1; SMN2MAPK1RAB9AKMT2ANOTUM
SCHEMBL6289523 0.90 SMN1; SMN2 (0.40) SMN1; SMN2MAPK1RAB9AKMT2ANOTUM
SCHEMBL6289522 0.90 SMN1; SMN2 (0.40) SMN1; SMN2MAPK1RAB9AKMT2ANOTUM
SCHEMBL6286795 0.88 SMN1; SMN2 (0.39) SMN1; SMN2MAPK1KMT2ANOTUMALDH1A1
SCHEMBL6286791 0.88 SMN1; SMN2 (0.39) SMN1; SMN2MAPK1KMT2ANOTUMALDH1A1
SCHEMBL6286693 0.87 NOTUM (0.37) SMN1; SMN2MAPK1RAB9AKMT2ANOTUM
SCHEMBL6287628 0.87 NOTUM (0.37) SMN1; SMN2MAPK1RAB9AKMT2ANOTUM
SCHEMBL6286691 0.87 NOTUM (0.37) SMN1; SMN2MAPK1RAB9AKMT2ANOTUM
SCHEMBL6289968 0.85 MAPK1 (0.36) SMN1; SMN2MAPK1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059685-A1 Pyridopyrimidine compounds and their uses CELL THERAPEUTICS, INC. (US) 2005-03-17 US disclosed
US-6825180-B2 CYTOKINE INTRACELLULAR SIGNALING INHIBITORS; ANTIINFLAMMATORY AGENTS CELL THERAPEUTICS, INC. 2004-11-30 US disclosed
US-20040023995-A1 Pyridopyrimidine compounds and their uses CELL THERAPEUTICS, INC. 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023995-A1 Pyridopyrimidine compounds and their uses PLPBP, MAVS, PDXK SMN1; SMN2 1228/4885MAPK1 97/4885RAB9A 2198/4885
US-20050059685-A1 Pyridopyrimidine compounds and their uses PLPBP, MAVS, PDXK SMN1; SMN2 1228/4885MAPK1 97/4885RAB9A 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.